Kornimate/medical-research-clean huggingface dataset:
efficacy and safety of linggui yangyuan paste in patients with male infertility

Conditions: Male Infertility; Asthenozoospermia; Oligoasthenozoospermia

Summary: male infertility affects millions of males worldwide and is rising in prevalence due to social and environmental conditions. asthenozoospermia (azs) and oligoasthenozoospermia (oa) are the major causes of male infertility. the diagnosis of male infertility has a negative effect on men's physical and psychological status, poses a threat to their social relationships, lowers self-esteem, and disrupts family harmony. at present, the treatment of asz and oa are all mostly empirical, including antioxidants, endocrine therapy, and anti-infection. however, there are still limitations due to inefficiencies. linggui yangyuan paste (lgyy), a traditional chinese compound herbal past, had been used to treat asz and oa for several years at the xiyuan hospital of china academy of chinese medical sciences. the investigators designed this program to study the efficacy and safety of lgyy for the treatment of patients with male infertility (azs and oa).


Eligibility criteria:
inclusion criteria: * the participants must meet all following criteria at the time of randomization to be eligible for recruitment : 1. study participants met the diagnostic criteria for male infertility 1)inability to have a child after at least 1 year of marriage with regular sexual life and without using any preventive methods 2)normal fertile female partner 2. study participants met the diagnostic criteria for azs or oa for azs: 1. sperm concentration ≥15 × 106/ ml 2. pr \<32% for oa: 1. sperm concentration \<15 × 106/ ml 2. pr \<32% (3) study participants met the tcm diagnosis criteria for kidney deficiency and blood stasis (4) men aged 22 to 45 years (5) the participants signed informed consent forms exclusion criteria: * the trial exclusion criteria included any of the following: 1. infertility is caused by the inability to complete sexual intercourse, including but not limited to erectile dysfunction or ejaculatory disorders 2. with infertility caused by organic lesions of the reproductive system 3. with reproductive system infection, such as chlamydia trachomatis or mycoplasma infection 4. with palpable varicocele 5. with abnormal and clinical significance of sex hormone (fsh, lh, t) 6. complicated with liver and kidney dysfunction, severe basic diseases such as diabetes, cardiovascular and cerebrovascular diseases, mental diseases, malignant tumors, or serious organic diseases 7. with a history of allergy to any medicine or ingredients used in this study 8. receive other relevant treatment for the disease 2 weeks before treatment
different timing for early laparoscopic cholecystectomy in acute calcular cholecystitis

Conditions: Acute Cholecystitis

Summary: the ideal timing for elc continues to be debatable in patients with acute calculator cholecystitis (acc). this study was planned to identify the impact of different elc timing in acc on surgical outcomes in terms of safety and efficacy

this multicentric analysis involved of successive patients with acc elc between april 2018 and march 2020. patients were divided into three groups according to the timing of the surgery: from the onset of symptoms within the first 3 days (group 1), between 4 and 7 days (group 2), and beyond 7 days (group 3). the primary outcome was the incidence of postoperative complications the secondary outcomes were conversion rate, blood loss, operative times, operational difficulty, the cost-benefit relationship, postoperative stay with each treatment line.

Eligibility criteria:
inclusion criteria: acc patients who underwent early lc exclusion criteria: pregnancy, acalculous cholecystitis, cbds, ascending cholangitis, pancreatitis, asa score 4, patients scheduled for dlc with failed medical treatment.

Keywords: early laparoscopic cholecystectomy postcholecystectomy bile injury delay laparoscopic cholecystectomy
when asking the indication of a skin biopsy from a patient with a leg ulcer in primary care?

Conditions: Varicose Ulcer; Leg Ulcer

Summary: leg ulcers are frequent. there are no epidemiological studies available in france, but international studies estimate the prevalence between 0.045 and 0.63% of the total population, prevalence increases with age, reaching 5% of patients over 80 years. extrapolating these prevalences in the french population between 28 000 and 395 000 people are affected in france a leg ulcer. it is a costly disease. in 2001, a french study conducted among 800 physicians, including 85.7% of general practitioners, involving more than 1000 patients with venous ulcers, it was estimated that the total cost of treatment per patient average was 888 32 euros. this is truly a public health problem. leg ulcers are in 80% of cases of vascular causes (venous, arterial or arteriovenous mixed). however, there are rare causes of ulcers: skin carcinoma, infectious ulcers and vasculitis. these ulcers rare causes require specific treatments that can often heal. to diagnose, to perform a skin biopsy. thus, the general practitioner must know when to put the indication for biopsy of a leg ulcer.

goal : analyzing the last 100 consecutive skin biopsies performed in patients carriers of chronic leg ulcers, followed in the vascular medicine department of the hospital saint joseph paris, to determine: * the reasons which motivated the doctor make the indication of biopsy: * disease duration of ulcer * unusual clinical features * other signs associated with ulcer * absence of a satisfactory explanation vascular * the pathological results purpose: to clear a typical profile ulcers biopsy methodology : * retrospective, single-center, * acquisition of data: via the pathology laboratory of the hospital will be collected the last 100 consecutive biopsies performed with leg ulcers in vascular medicine department of the hospital saint joseph paris, between 1 january 2013 and the october 1, 2013. then be analyzed all paper and electronic records of these patients. * grid and analysis: * patient histories, * vascular profile of patients, * clinical and chronological criteria of the ulcer, * other signs associated with ulcer * results of histological biopsies. * the data will be made anonymous on the grid for collection by a numbering system 1 100.

Eligibility criteria:
inclusion criteria: * the last 100 consecutive skin biopsies performed in patients carriers of chronic leg ulcers, hospitalized in the vascular medicine department of the hospital saint joseph paris exclusion criteria: * no exclusion criteria
fully constrained acetabular liner vs. dual mobility hip joint in the surgical treatment of metastatic bone disease of the hip

Conditions: Metastatic Cancer to the Hip

Summary: the purpose of the current study is to investigate whether dual mobility liners are non-inferior til constrained liners regarding the post-operative hip joint dislocation risk following total hip replacement in patients with metastatic bone disease of the hip.

the use of constrained liners in total hip arthroplasty (tha) in patients with metastatic bone disease of the hip (mbd) has increased at our department in recent years to avoid hip dislocation in this high-risk population. hip surgeons seldom recommend the use of constrained liners in primary surgery due to the risk of polyethylene wear and high revision rates. an alternative to constrained liners are dual mobility cups, which have been shown to decrease the risk of dislocation in other high-risk tha operations such as revision tha and tha in hip fracture patients, while providing the added benefit of a less restricted range of motion of the joint. this study will investigate whether dual mobility cups are non-inferior to constrained liners regarding the post-operative joint dislocation risk in patients with mbd.

Eligibility criteria:
inclusion criteria: * diagnosed with metastatic bone disease of the hip defined as bone lesions in the proximal femur because of secondary malignant growth of a primary cancer located elsewhere or bone lesions in the proximal femur due to hematological malignancies * determined eligible for total hip arthroplasty for metastatic bone disease of the hip and is planned to undergo surgery at the study site * provides informed consent prior to initiation of any study-specific activities/procedures exclusion criteria: * previous osteosynthesis or endoprosthetic surgery of the ipsilateral hip * pelvic reconstruction of the ipsilateral hip * total femoral replacement of the ipsilateral femur * it is not surgically viable to insert an acetabular cup and/or a femoral stem * subject is currently or has previously been enrolled in this study * subject is incapable of understanding the patient information or unable to provide informed consent

Keywords: metastatic bone disease total hip arthroplasty hip replacement constrained liner dual mobility orthopaedic oncology
effect of nutritional counseling based on diet quality on metabolic control in patients with type 2 diabetes mellitus

Conditions: Type 2 Diabetes Mellitus

Summary: randomized clinical trial with outpatient patients with type 2 diabetes mellitus treated in endocrinology division, hospital de clinicas de porto alegre. the study aims to carry out a nutritional counseling directed to offer benefits in metabolic control in diabetic patients.

randomized clinical trial with outpatient patients with type 2 diabetes mellitus treated in endocrinology division, hospital de clinicas de porto alegre. the study aims to carry out a nutritional counseling directed to offer benefits in metabolic control in diabetic patients. the initial step will be performed analysis of composition and diet quality, and anthropometric and laboratory evaluation. after initial assessment and meeting the criteria eligibility, patients will be randomized to receive nutritional counseling from diet quality (intervention group) or usual diet in according to current nutritional recommendations (control group). both the groups will receive adjust caloric intake as the nutritional needs of each patient. patients will be followed over six months, on a monthly basis from hospital visits or telephone monitoring. the outcomes evaluated will be: the achievement of therapeutic targets (fasting blood glucose levels between 70-130 mg / dl, hba1c\<7%, ldl cholesterol \<100 mg/dl and triglycerides \<150 mg/dl); use of antidiabetic drugs, lipid-lowering and antihypertensive drugs, and adherence to necessary dietary changes.

Eligibility criteria:
inclusion criteria: * type 2 diabetes patients aged ≥ 30 years; * body mass index ≤ 40kg/m²; * serum creatinine \<2 mg/dl; * serum triglycerides \<400 mg/dl. exclusion criteria: * cognitive impairment (clinical suspicion); * illiterate; * liver function tests and abnormal thyroid; * urinary tract infection carriers, kidney disease and heart failure uncompensated (grade iii or iv); * active wasting disease diagnosis (cancer, acquired immune deficiency syndrome); * metabolic control within the therapeutic target; * patients with dietary guidance by nutritionist in less than three months.

Keywords: nutritional counseling diet
combined tdcs and vision restoration training in subacute stroke rehabilitation: a pilot study

Conditions: Hemianopia; Stroke

Summary: the purpose of this study is to determine whether non-invasive transcranial direct current stimulation (tdcs) is effective in increasing rehabilitation effects after stroke in visual cortex.

visual field defects after posterior cerebral artery stroke can be improved by vision restoration training (vrt), but when combined with transcranial direct current stimulation (tdcs) which alters brain excitability, vision restoration can be potentiated in the chronic stage. because it is possible that such therapy may be more effective during the early recovery phase after the stroke and can reach patients during the rehabilitation phase, investigators wished to explore the applicability, efficacy and safety of early intervention with a combined tdcs/vrt treatment. seven post-acute stroke homonymous hemianopia patients were assigned to 10 sessions of combined tdcs (2ma, 10 daily sessions of 15-20 min) and vrt. the primary outcome criterion was the pre-post change in perimetric detection thresholds in percent. the results were compared to 7 age and stroke lesion matched controls of our patient data pool who received standard rehabilitation.

Eligibility criteria:
inclusion criteria: * posterior cerebral artery stroke * visual field defect * lesion age 4 weeks up to 6 month max exclusion criteria: * electrical implants * metal artefacts in head * epilepsy * visual neglect
effect of raltegravir on endothelial function in hiv-infected patients

Conditions: HIV Infection; Inflammation; Cardiovascular Disease; HIV Infections

Summary: recent studies suggest that hiv patients are at increased risk for cardiovascular events; however, the mechanisms underlying this increased risk remain unclear. our group was one of the first to demonstrate that hiv infection is independently associated with accelerated atherosclerosis, as measured by carotid artery-intima media thickness (imt), and that hiv-associated inflammation may be driving this accelerated atherosclerosis. the mechanism by which hiv disease independent of any drug-specific toxicity increases the risk of cardiovascular disease during haart is not known. we hypothesize that even well controlled hiv infection is independently associated with cardiovascular risk and that further decreasing hiv-associated inflammation adding newer antiretroviral agents will also decrease cardiovascular risk. we will perform a small clinical trial of approximately 50 hiv-infected patients each to study the relationship between hiv infection, inflammation, thrombosis, atherogenic lipoproteins, and measures of atherosclerosis. we propose the following specific aims: aim 1: to determine the influence of traditional and novel markers of inflammation on endothelial function and imt progression; aim 2: to determine if "intensification" with raltegravir in subjects on long-term antiretroviral therapy with clinically undetectable hiv rna levels will improve endothelial function, and to determine if this effect is mediated by alterations in inflammatory markers, lipoproteins and/or thrombotic factors. for aim 2, subjects from 2 randomized, double-blind, placebo-controlled raltegravir intensification studies will be asked to co-enroll in this cardiovascular study.


Eligibility criteria:
inclusion criteria: 1. stable antiretroviral therapy for at least 12 months 2. all plasma hiv rna levels within the past year must be below level of detection (\ 50 but \< 200 copies will be allowed. 3. screening plasma hiv rna levels \< 50 copies rna/ml 4. \>90% adherence to therapy within the preceding 30 days, as determined by self-report 5. females of childbearing potential must have a negative serum pregnancy test at screening and agree to use a double-barrier method of contraception throughout the study period. 6. cd4\ =350 cells/mm3 for at least one year ("immunologic responder"). exclusion criteria: 1. ongoing or prior use of any integrase inhibitor or r5 inhibitor. 2. patients who plan to modify existing antiretroviral therapy in the next 24 weeks for any reason 3. serious illness requiring hospitalization or parental antibiotics within preceding 3 months 4. concurrent or recent exposure to any immunomodulatory drugs 5. advanced liver disease or active hepatitis b or c 6. patients with systolic blood pressure \<100/70 7. starting or stopping statin therapy during the trial

Keywords: hiv endothelium inflammation treatment experienced
factor xiii in major burns coagulation

Conditions: Burns; Coagulation Disorder; Factor XIII Deficiency; Cicatrization; Endothelial Dysfunction

Summary: prospective observational study in which fxiii levels and coagulation tests and cicatrization are measured during the 30 days after the thermal trauma.

this is a prospective observational pilot study in which the levels of fxiii and coagulation, anticoagulation, fibrinolysis, endothelial tissue damage and cicatrization are at the arrival of the patient to hospital, 24 hours before the first surgical intervention, 24h after the first surgical intervention, at 7 days after the first intervention and at 30 days after the thermal trauma, in this moment the healing will also be evaluated. all burn patients who meet the proposed inclusion criteria will be included and entered into the burn unit of the vall d'hebron university hospital from the start of the study until reaching a minimum of 20 cases or a temporary term of 2 years.

Eligibility criteria:
inclusion criteria: * burned patients with a burned body surface of 20% or more * over 18 years of age exclusion criteria: * absi (abbreviated burns severity index) greater than or equal to 12 * associated polytrauma * coagulation deficit previously known * treatment with anticoagulants * electrocution burns * admission into the unit after hour 6 after thermal trauma * the refusal of the patient, familiar or responsible to participate in the study

Keywords: burns coagulation factor xiii glycocalix cicatrization
levant i, the lutonix paclitaxel-coated balloon for the prevention of femoropopliteal restenosis

Conditions: Atherosclerosis; Vascular Disease; Arteriosclerosis

Summary: the purpose of the study is to assess the safety and efficacy of the lutonix catheter for treatment of stenosis of the femoropopliteal arteries by direct comparison to standard balloon angioplasty.

the levant i trial will enroll patients presenting with clinical evidence of claudication or critical limb ischemia and an angiographically significant lesion in the femoropopliteal arteries. patients will be randomized to treatment with either the lutonix catheter or standard balloon angioplasty after predilation.

Eligibility criteria:
inclusion criteria: clinical criteria * male or non-pregnant female ≥18 years of age. * rutherford clinical category 2-5 * patient is willing to provide informed consent and comply with the required follow up visits, testing schedule, and medication regimen angiographic criteria * a single de novo or restenotic atherosclerotic lesion \>70% in the sfa or popliteal artery that is ≥4 cm and ≤15 cm in total length. * reference vessel diameter ≥4 mm and ≤ 6mm * successful wire crossing of lesion * a patent inflow artery free from significant lesion (\>50% stenosis) as confirmed by angiography (treatment of target lesion acceptable after successful treatment of inflow artery lesions) exclusion criteria: * pregnant or planning on becoming pregnant in \< 2yrs * live expectancy of \<2 years * patient actively participating in another investigational device or drug study * history of hemorrhagic stroke within 3 months * previous or planned surgical or interventional procedure within 30 days of index procedure * chronic renal insufficiency with creatinine \>2.5 mg/l * prior surgery of the target lesion * inability to take required study medications * anticipated use of iib/iiia inhibitor prior to randomization * lesion length is \ 15 cm or there is no normal proximal arterial segment in which duplex ultrasound velocity ratios can be measured * known inadequate distal outflow * significant inflow disease * acute or sub-acute thrombus in target vessel * severe lesion calcification * acute vessel occlusion or sudden symptom onset * use of adjunctive therapies (i.e. laser, atherectomy, cryoplasty, scoring/cutting balloon, etc.) * prior participation in the current study

Keywords: drug coated balloon sfa disease femoropopliteal disease angioplasty pad paclitaxel tubulin modulators antineoplastic agents mitosis modulators balloon angioplasty local drug delivery restenosis drug-coated balloon
evaluation of direct effects of electric fields on brain

Conditions: Epilepsy

Summary: transcranial current stimulation (tcs), a safe, tolerable technique employing weak currents (\~ 1 ma) applied to the scalp, has been shown to be a promising technique in alleviating seizures in focal epilepsy patients. although studies reveal a decrease in the epileptiform activity due to tcs, this field lacks a quantification of neurophysiological changes during and immediately after stimulation. the investigators hypothesise that tcs can effectively reduce the amplitude and rate of interictal spikes as well as the functional connectivity between regions during and immediately after stimulation. it is thus planned to deliver an extensive quantitative description of the tcs effects on interictal spike activity, functional connectivity and other tissue biomarkers, using the simultaneous recording of intracranial signals during tcs. moreover, the investigators seek to compare these variations between different tcs paradigms (direct current -tdcs- vs alternate current -tacs- stimulation).


Eligibility criteria:
inclusion criteria: 1. provision of signed and dated informed consent form 2. male or female, aged ≥ 18 years old 3. focal drug-resistant epilepsy 4. patient undergoing a clinical seeg investigation 5. stated willingness to comply with all study procedures and availability for the duration of the study 6. patient affiliated or beneficiary of a health insurance plan 7. patient for whom mri images (3d t1) are exploitable and fit with the minimum mri requirements needed for biophysical modelling (cf annex in 14.), prior to seeg electrodes implantation 8. patient for whom a ct-scan with electrodes (or mri with electrodes) has been realized after seeg procedure. exclusion criteria: 1. difficulty to read or understand the french language, or inability to understand the information regarding the study 2. person protected by articles l1121-5, l1121-6 and l1121-8 of public health code (pregnant or breastfeeding woman, deprived of liberty by judicial decision, situations of social fragility, adults or unable to express their consent). pregnancy will be evaluated during screening with a urine pregnancy test. 3. presence of severe negative outcome of seeg surgery preventing the acquisition of seeg data (i.e. hemorragic complications, subcutaneous infection), at the time of inclusion. 4. patient showing contraindications for electric stimulation at the time of inclusion: (a) patient with unstable or non-controlled neuropsychiatric illness (b) patients having cardiac or medication implants (c) patients with implanted pacemakers (d) patients with serious brain injury (e) patients showing damage of skin at sites of stimulation 5. any condition that, according to the investigator, is not compatible with carrying out the study

Keywords: tdcs (transcranial direct current stimulation) tacs (transcranial alternate current stimulation) starstim transcranial stimulation seeg (stereoelectroencephalography)